ATE200662T1 - Lipopolyamine als transfektionsmittel und ihre pharmaceutische verwendung - Google Patents

Lipopolyamine als transfektionsmittel und ihre pharmaceutische verwendung

Info

Publication number
ATE200662T1
ATE200662T1 AT95941760T AT95941760T ATE200662T1 AT E200662 T1 ATE200662 T1 AT E200662T1 AT 95941760 T AT95941760 T AT 95941760T AT 95941760 T AT95941760 T AT 95941760T AT E200662 T1 ATE200662 T1 AT E200662T1
Authority
AT
Austria
Prior art keywords
grouping
pct
general formula
date jun
radical
Prior art date
Application number
AT95941760T
Other languages
English (en)
Inventor
Gerardo Byk
Catherine Dubertret
Daniel Scherman
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE200662T1 publication Critical patent/ATE200662T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95941760T 1994-12-05 1995-12-04 Lipopolyamine als transfektionsmittel und ihre pharmaceutische verwendung ATE200662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9414596A FR2727679B1 (fr) 1994-12-05 1994-12-05 Nouveaux agents de transfection et leurs applications pharmaceutiques
PCT/FR1995/001595 WO1996017823A1 (fr) 1994-12-05 1995-12-04 Lipopolyamines comme agents de transfection et leurs applications pharmaceutiques

Publications (1)

Publication Number Publication Date
ATE200662T1 true ATE200662T1 (de) 2001-05-15

Family

ID=9469480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941760T ATE200662T1 (de) 1994-12-05 1995-12-04 Lipopolyamine als transfektionsmittel und ihre pharmaceutische verwendung

Country Status (22)

Country Link
US (1) US6107286A (de)
EP (1) EP0796240B1 (de)
JP (1) JPH10509958A (de)
KR (1) KR100447517B1 (de)
AT (1) ATE200662T1 (de)
AU (1) AU713662B2 (de)
BR (1) BR9510080A (de)
CA (1) CA2208184A1 (de)
CZ (1) CZ289513B6 (de)
DE (1) DE69520748T2 (de)
DK (1) DK0796240T3 (de)
ES (1) ES2157351T3 (de)
FI (1) FI972366A0 (de)
FR (1) FR2727679B1 (de)
GR (1) GR3035759T3 (de)
HU (1) HUT77171A (de)
IL (1) IL116251A (de)
NO (1) NO972566L (de)
PT (1) PT796240E (de)
SK (1) SK282601B6 (de)
WO (1) WO1996017823A1 (de)
ZA (1) ZA9510326B (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
FR2756491B1 (fr) * 1996-11-29 1999-01-08 Rhone Poulenc Rorer Sa Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
US7097854B2 (en) 1996-09-12 2006-08-29 Medigene Oncology Gmbh Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds
FR2754272B1 (fr) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa Procede de preparation de compositions pour le transfert d'acides nucleiques
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6884430B1 (en) * 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
AU753781B2 (en) 1997-04-28 2002-10-31 Aventis Pharma S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
BR9907269A (pt) 1998-01-30 2001-04-03 Aventis Pharma Sa Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças.
KR20010042318A (ko) * 1998-04-02 2001-05-25 아방티 파르마 소시에테 아노님 신규 핵산 전달제, 이를 함유하는 조성물 및 용도
FR2777017B1 (fr) * 1998-04-02 2002-08-23 Rhone Poulenc Rorer Sa Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
US6583301B1 (en) 1998-04-08 2003-06-24 Celltech R & D Limited Lipids
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
WO2000064858A1 (en) * 1999-04-26 2000-11-02 Celltech R&D Limited Bipolar lipids and their use for the delivery of bioactive substances
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
WO2001040254A1 (en) * 1999-12-02 2001-06-07 Tomohiko Ohwada Reagents for gene transfer
ATE511856T1 (de) 2000-03-13 2011-06-15 Cornell Res Foundation Inc Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
KR100373844B1 (ko) * 2000-09-21 2003-02-26 굿젠 주식회사 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
KR100373845B1 (ko) * 2000-09-21 2003-02-26 굿젠 주식회사 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
BR0116756A (pt) 2000-12-28 2005-01-04 Wyeth Corp Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
EP1534738B1 (de) 2001-02-20 2012-06-20 Intrexon Corporation Neue substitutionsmutantenrezeptoren und ihre verwendung in einem induzierbaren genexpressionsystem auf grundlage eines nukleären rezeptors
CA2438119C (en) 2001-02-20 2014-12-16 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
ES2385598T3 (es) 2001-02-20 2012-07-27 Intrexon Corporation Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP1499349B1 (de) 2001-03-02 2009-11-18 The Rockefeller University Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
JP2005532781A (ja) 2001-09-26 2005-11-04 レオジーン・ホールディングス，インコーポレーテッド ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
EP1490686A2 (de) 2001-09-26 2004-12-29 RheoGene Holdings Inc. Weisse-fliege-ecdyson-rezeptor-nukleinsäuren, -polypeptide und ihre verwendungen
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1479985B1 (de) 2002-01-17 2017-06-14 Alfa Laval Corporate AB Getauchter Verdampfer umfassend einen Plattenwärmetauscher und ein zylindrisches Gehäuse in dem der Plattenwärmetauscher angeordnet ist
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7304161B2 (en) * 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) * 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
DK1745295T3 (da) 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
CA2562833A1 (en) 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US7306923B2 (en) 2004-06-14 2007-12-11 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
EP2397490B1 (de) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Impfstoffkonstrukte und Impfstoffkombinationen zur Verbesserung der Breite der Immunantwort auf verschiedene HIV-Stränge und -Clades
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
US8088382B2 (en) 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
WO2007028147A2 (en) 2005-09-01 2007-03-08 Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
MY151438A (en) 2006-07-28 2014-05-30 Sanofi Aventis Compositions and method for treatment of tumors
PL2068922T3 (pl) 2006-10-19 2012-11-30 Csl Ltd Przeciwciała anty-IL-13R alfa1 i ich zastosowania
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
CA2673622A1 (en) * 2006-12-22 2008-07-03 Imuthes Limited Lipid
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
MX363066B (es) 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
HRP20140405T1 (hr) 2007-06-20 2014-06-20 Galapagos N.V. Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova
US20090069266A1 (en) 2007-06-27 2009-03-12 Northwestern University Methods and compositions for nucleic acid transfer into cells
US20090098055A1 (en) 2007-08-23 2009-04-16 Intrexon Corporation Methods and Compositions for Diagnosing Disease
MX2010002777A (es) * 2007-09-17 2010-05-21 Rohm & Haas Composiciones y metodos para modificacion de respuestas fisiologicas en plantas.
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
JP2010539993A (ja) 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
EP2331071A1 (de) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Neue multimodulare anordnung zur intrazellulären abgabe
AU2009290848A1 (en) 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
EP2398480A1 (de) 2009-02-19 2011-12-28 Galapagos N.V. Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
US20120004160A1 (en) 2009-02-19 2012-01-05 Glaxo Group Ltd. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398481A2 (de) 2009-02-19 2011-12-28 Galapagos N.V. Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
EP3043179B1 (de) 2009-04-01 2020-05-06 Galapagos N.V. Verfahren und mittel zur behandlung von osteoarthritis
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011116351A2 (en) 2010-03-19 2011-09-22 University Of South Alabama Methods and compositions for the treatment of cancer
EP2550359B1 (de) 2010-03-23 2017-08-09 Intrexon Corporation Vektoren zur bedingten expression therapeutischer proteine, wirtszellen mit diesen vektoren und verwendungen davon
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CN103476928B (zh) 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
EP2681327B1 (de) 2011-03-04 2018-11-21 Intrexon Corporation Vektoren für bedingte proteinexpression
US9458456B2 (en) 2011-04-01 2016-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
EP2788478B1 (de) 2011-12-09 2017-08-23 Institut Pasteur Multiplex-immunoscreening-test
WO2013103401A1 (en) 2012-01-06 2013-07-11 University Of South Alabama Methods and compositions for the treatment of cancer
CZ201220A3 (cs) * 2012-01-13 2013-07-17 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Lipopolyaminy sperminového typu pro konstrukci liposomálních transfekcních systému
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
JP6437467B2 (ja) 2013-03-14 2018-12-19 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
US9952202B2 (en) 2013-03-14 2018-04-24 Galapagos Nv Methods of identifying compounds for the treatment of fibrosis by using S1PR5
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
ES2683329T3 (es) 2013-03-15 2018-09-26 Intrexon Corporation Diacilhidrazinas que contienen boro
WO2014193800A2 (en) 2013-05-28 2014-12-04 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3194359B1 (de) 2014-09-17 2020-04-08 Intrexon Corporation Borhaltige diacylhydrazinverbindungen
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10619159B2 (en) 2016-01-19 2020-04-14 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference for inhibition of KRAS
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
AU2017359342B2 (en) 2016-11-09 2022-02-17 Intrexon Corporation Frataxin expression constructs
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US12440578B2 (en) 2017-02-22 2025-10-14 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
EP3539975A1 (de) 2018-03-15 2019-09-18 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Mikropeptide und verwendungen davon
JP7539161B2 (ja) 2018-08-10 2024-08-23 ユーティレックス カンパニー リミテッド Ｈｌａ－ｄｒに結合するキメラ抗原受容体およびｃａｒ－ｔ細胞
EP3852911B1 (de) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
BR112021017770A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3161098A1 (en) * 2020-01-03 2021-07-08 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
AU2021205416B2 (en) 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
EP3885440A1 (de) 2020-03-26 2021-09-29 Splicebio, S.L. Spaltinteine und deren verwendungen
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US12534540B2 (en) 2023-01-23 2026-01-27 Clemson University Research Foundation CYP1A1-targeted monoclonal antibody with reactivity across vertebrate taxa
WO2025109139A1 (en) 2023-11-23 2025-05-30 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Rodent models obtained by knock-in of the human her2 gene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE757840A (fr) * 1969-10-23 1971-04-22 Basf Ag Procede de preparation d'amines a partir d'alcools
US4014933A (en) * 1969-10-23 1977-03-29 Basf Aktiengesellschaft Production of amines from alcohols
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production

Also Published As

Publication number Publication date
HUT77171A (hu) 1998-03-02
GR3035759T3 (en) 2001-07-31
FI972366A7 (fi) 1997-06-04
FI972366L (fi) 1997-06-04
AU713662B2 (en) 1999-12-09
MX9703928A (es) 1998-05-31
ZA9510326B (en) 1996-06-11
NO972566D0 (no) 1997-06-05
FR2727679B1 (fr) 1997-01-03
KR100447517B1 (ko) 2004-11-20
NO972566L (no) 1997-06-05
BR9510080A (pt) 1997-12-30
CA2208184A1 (fr) 1996-06-13
FI972366A0 (fi) 1997-06-04
WO1996017823A1 (fr) 1996-06-13
FR2727679A1 (fr) 1996-06-07
JPH10509958A (ja) 1998-09-29
US6107286A (en) 2000-08-22
ES2157351T3 (es) 2001-08-16
SK282601B6 (sk) 2002-10-08
PT796240E (pt) 2001-09-28
EP0796240B1 (de) 2001-04-18
AU4307296A (en) 1996-06-26
CZ171197A3 (cs) 1998-03-18
IL116251A (en) 2000-11-21
DK0796240T3 (da) 2001-05-07
IL116251A0 (en) 1996-03-31
CZ289513B6 (cs) 2002-02-13
EP0796240A1 (de) 1997-09-24
DE69520748D1 (de) 2001-05-23
SK70197A3 (en) 1997-11-05
DE69520748T2 (de) 2001-09-13

Similar Documents

Publication Publication Date Title
DE69520748D1 (de) Lipopolyamine als transfektionsmittel und ihre pharmaceutische verwendung
ZA969489B (en) Novel transfection agents and their pharmaceutical applications
DE59913103D1 (de) Substituierte 4-amino-2-aryl-cyclopenta ädüpyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
TW365602B (en) New farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions which contain them
DE60015795D1 (de) Geruchsneutralisierungsmittel
MX9603314A (es) Composiciones que contienen nebivolol micronizado.
AU8729791A (en) Pharmaceutical formulations
MY134582A (en) New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments
MY115211A (en) Novel amino acid derivatives, their preparation and use
DE60014133D1 (de) Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln
BG106235A (en) Streptogramin derivatives, preparation and compositions containing them
AU3613489A (en) Improvements in or relating to insecticidal agents containing acylated alpha-amino acid ester derivatives
AU3258197A (en) Peptides
WO2003039594A3 (en) Antigen presenting vesicles
BG103194A (en) Pharmaceutical products for the treatment and prevention of diseases caused by the impairment of the vascular endothelial cells
MX9708735A (es) Benzotiazoles y benzoxazoles, composiciones farmaceuticas que contienen estos compuestos y su uso y proceso para prepararlos.
TW369531B (en) New taxoids, their preparation and pharmaceutical compositions containing them
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
IT1273455B (it) Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
ATE260261T1 (de) Oligobenzimidazolderivate und ihre verwendung als dna-transfektionsmittel
IT1277736B1 (it) Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
MX9802679A (es) Derivados de ditiolan, su preparacion y su efecto terapeutico.
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee